Cited by 1,626Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and TreatmentsLiver Diseases and Immunity

The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Open access

Ilyas, Sumera I., Khan, Shahid A., Hallemeier, Christopher L., Kelley, Robin K., Gores, Gregory J.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.157PMC PMC5819599

Open this paper in CoChat — free account

Abstract

Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.157

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,157
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,858
Self-citation
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J. A., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J., Patel, T. C., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,530
Self-citation
Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
Jarnagin, W. R., Fong, Y., DeMatteo, R. P., Gönen, M., Burke, E. C., Bodniewicz, J., Youssef, M., Klimstra, D., & Blumgart, L. H. (2001) · Annals of Surgery · doi:10.1097/00000658-200110000-00010 · Cited by 1,342
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,331
Self-citation
Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
Schnitzbauer, A. A., Lang, S. A., Goessmann, H., Nadalin, S., Baumgart, J., Farkas, S. A., Fichtner‐Feigl, S., Lorf, T., Goralcyk, A., Hörbelt, R., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31824856f5 · Cited by 1,330
Genomic spectra of biliary tract cancer
Nakamura, H. K., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,306
Cholangiocarcinoma
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,301
Cholangiocarcinoma
Nakeeb, A., Pitt, H. A., Riall, T. S., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,207
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
The Epidemiology of Cholangiocarcinoma
Shaib, Y. H., & El‐Serag, H. B. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,134
Intrahepatic Cholangiocarcinoma
Endo, I., Gönen, M., Yopp, A. C., Dalal, K. M., Zhou, Q. C., Klimstra, D. S., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Schwartz, L. H., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 867
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 787
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Sundaram, S. K., Khazanov, N. A., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 759
Radiation-Associated Liver Injury
Pan, C. C., Kavanagh, B. D., Dawson, L. A., Li, X. A., Das, S. K., Miften, M. M., & Haken, R. K. T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.092 · Cited by 755
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., Nagino, M., Kondo, S., Nagaoka, S., Funai, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605779 · Cited by 745
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 689
Self-citation
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
Shaib, Y. H., Davila, J. A., McGlynn, K. A., & El‐Serag, H. B. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.030 · Cited by 682
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 624
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers
Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597
Self-citation
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Tse, R. V., Hawkins, M., Lockwood, G. A., Kim, J. J., Cummings, B., Knox, J. J., Sherman, M., & Dawson, L. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3529 · Cited by 590
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Solé, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 577
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
Khan, S. A., Taylor-Robinson, S. D., Toledano, M. B., Beck, A. J., Elliott, P., & Thomas, H. C. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00297-0 · Cited by 571
Self-citation
Radiation Dose–Volume Effects in the Stomach and Small Bowel
Kavanagh, B. D., Pan, C. C., Dawson, L. A., Das, S. K., Li, X. A., Haken, R. K. T., & Miften, M. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.071 · Cited by 549
Cholangiocarcinoma: lessons from Thailand
Sripa, B., & Pairojkul, C. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbf9b3 · Cited by 532
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
Palmer, W. C., & Patel, T. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.022 · Cited by 520
Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
Chan-on, W., Nairismägi, M., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 495
Worldwide trends in mortality from biliary tract malignancies
Patel, T. C. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-10 · Cited by 491
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Hong, T. S., Wo, J. Y.-L., Yeap, B. Y., Ben‐Josef, E., McDonnell, E., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2710 · Cited by 474
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130142 · Cited by 457
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Rand, J. V., Jones, D., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 453
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R. T., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D. S., Meric‐Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis
Patel, A. H., Harnois, D. M., Klee, G. G., LaRusso, N. F., & Gores, G. J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01685.x · Cited by 424
Self-citation
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Ben‐Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., Thomas, C. R., Alberts, S. R., Dawson, L. A., Micetich, K. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2219 · Cited by 420
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vázquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 415
Hilar cholangiocarcinoma: expert consensus statement
Mansour, J. C., Aloia, T. A., Crane, C. H., Heimbach, J. K., Nagino, M., & Vauthey, J.-N. (2015) · HPB · doi:10.1111/hpb.12450 · Cited by 414
Epidemiology of cholangiocarcinoma
Bergquist, A. M., & von Seth, E. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.003 · Cited by 402
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis
Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H. S., Bridgewater, J. A., & Okusaka, T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt540 · Cited by 391
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Tabernero, J. M., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A. C., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 390
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998
Taylor-Robinson, S. D., Toledano, M. B., Arora, S., Keegan, T., Hargreaves, S., Beck, A. J., Khan, S. A., Elliott, P., & Thomas, H. C. (2001) · Gut · doi:10.1136/gut.48.6.816 · Cited by 380
Self-citation
Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment
Sapisochín, G., Facciuto, M. E., Rubbia‐Brandt, L., Martí, J. M., Mehta, N. J., Yao, F. Y., Vibert, É., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 369
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R., & Greco, F. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3755 · Cited by 365
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L. S., Shih, A. H., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 358
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Perera, T. P. S., Jovcheva, E., Mévellec, L., Vialard, J. E., Lange, D. D., Verhulst, T., Paulussen, C., Ven, K. V. D., King, P., Freyne, E. J. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0589 · Cited by 346
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K. S., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 343
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
Self-citation
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis
Tao, R., Krishnan, S., Bhosale, P., Javle, M. M., Aloia, T. A., Shroff, R. T., Kaseb, A. O., Bishop, A. J., Swanick, C. W., Koay, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3778 · Cited by 310
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D. M., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 308
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V. M., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307
The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival
Choi, S.-B., Kim, K. S., Choi, J., Park, S. W., Choi, J.-S., Lee, W. J., & Chung, J.-B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0631-1 · Cited by 304
Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma
Robles-Campos, R., Figueras, J., Turrión, V. S., Margarit, C., Moya, A., Varó, E., Calleja, J., Valdivieso, A., Valdecasas, J. C. G., López, P., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000108702.45715.81 · Cited by 303
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii‐Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L. W., Kauh, J. S. W., O’Neil, B. H., Balsom, S., Balint, C. R., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 301
Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma # †
Rimola, J., Forner, A., Reig, M., Vilana, R., de Lope, C. R., Ayuso, C., & Bruix, J. (2009) · Hepatology · doi:10.1002/hep.23071 · Cited by 297
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
Arbelaiz, A., Azkargorta, M., Krawczyk, M. J., Santos‐Laso, Á., Lapitz, A., Perugorria, M. J., Erice, O., González, E., Jiménez-Agüero, R., Casta, A. L., et al. (2017) · Hepatology · doi:10.1002/hep.29291 · Cited by 297
Self-citation
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Khan, S. A., Emadossadaty, S., Ladep, N. G., Thomas, H. C., Elliott, P., Taylor-Robinson, S. D., & Toledano, M. B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.015 · Cited by 290
Self-citation
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham, R. P., Fritcher, E. B. B., Pestova, E., Schulz, J., Sitailo, L., Vasmatzis, G., Murphy, S., McWilliams, R., Hart, S., Halling, K., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 289
Self-citation
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination
Heimbach, J. K., Sánchez, W., Rosen, C. B. B., & Gores, G. J. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00298.x · Cited by 287
Self-citation
Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
Horlad, H., Komohara, Y., Okabe, H., Masuda, T., Ohnishi, K., Lei, X., Beppu, T., Baba, H., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01614.x · Cited by 280
Liver transplantation for cholangiocarcinoma
Rosen, C. B., Heimbach, J. K., & Gores, G. J. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01108.x · Cited by 271
Self-citation
Cancer of Unknown Primary Site
Varadhachary, G. R., & Raber, M. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1303917 · Cited by 267
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Fritcher, E. G. B., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 243
Self-citation
Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience
Mohamadnejad, M., DeWitt, J. M., Sherman, S., LeBlanc, J. K., Pitt, H. A., House, M. G., Jones, K. J., Fogel, E. L., McHenry, L., Watkins, J. L., et al. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2010.08.050 · Cited by 239
Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001
West, J., WOOD, H. E., Logan, R. F., Quinn, M. J., & Aithal, G. P. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603127 · Cited by 234
Human bile contains MicroRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis
Li, L., Masica, D. L., Ishida, M., Tomuleasa, C., Umegaki, S., Kalloo, A. N., Georgiades, C. S., Singh, V. K., Khashab, M. A., Amateau, S. K., et al. (2014) · Hepatology · doi:10.1002/hep.27050 · Cited by 224
Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival
Hoffmann, R., Paprottka, P. M., Schön, A., Bamberg, F., Haug, A. R., Dürr, E.-M., Rauch, B., Trumm, C., Jakobs, T. F., Helmberger, T. K., et al. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0142-x · Cited by 223
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., Nakamura, T., Ueno, M., Ariizumi, S.-I., Hà, N. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7120 · Cited by 223
Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Mertens, J. C., Fingas, C. D., Christensen, J. D., Smoot, R. L., Bronk, S. F., Werneburg, N. W., Gustafson, M. P., Dietz, A. B., Roberts, L. R., Sirica, A. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2130 · Cited by 215
Self-citation
Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis
Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J. J., & Parsi, M. A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.09.015 · Cited by 203
PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: Updated Survival Data
Aguiar, P. N., de Mello, R. A., Hall, P. S., Tadokoro, H., & Lopes, G. D. L., Jr. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 199
“Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?
Sapisochín, G., de Lope, C. R., Gastaca, M., de Urbina, J. O., Suárez, M. A., Santoyo, J. S., Castroagudı́n, J. F., Varó, E., López‐Andújar, R., Palacios, F., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12591 · Cited by 198
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Primrose, J. M., Fox, R., Palmer, D. H., Prasad, R. K., Mirza, D. F., Anthoney, D. A., Corrie, P., Falk, S. J., Wasan, H. S., Ross, P. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4006 · Cited by 190
Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma
Yachida, S., Wood, L. D., Suzuki, M., Takai, E., Totoki, Y., Kato, M., Luchini, C., Arai, Y., Nakamura, H. K., Hama, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.012 · Cited by 183
Serum and Bile Markers for Cholangiocarcinoma
Nehls, O., Gregor, M., & Klump, B. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828891 · Cited by 181
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Fontugne, J., Augustin, J., Pujals, A., Compagnon, P., Rousseau, B., Luciani, A., Tournigand, C., Cherqui, D., Azoulay, D., Pawlotsky, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15602 · Cited by 180
Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis
Ruys, A. T., Beem, B. E. V., Engelbrecht, M. R. W., Bipat, S., Stoker, J., & van Gulik, T. M. (2012) · British Journal of Radiology · doi:10.1259/bjr/88405305 · Cited by 175
External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma
Foo, M. L., Gunderson, L. L., Bender, C. E., & Buskirk, S. J. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00299-x · Cited by 175
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Silva, V. W. K., Askan, G., Daniel, T. D., Lowery, M. A., Klimstra, D. S., Abou‐Alfa, G. K., & Shia, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.10.04 · Cited by 169
Bile Proteomic Profiles Differentiate Cholangiocarcinoma From Primary Sclerosing Cholangitis and Choledocholithiasis §Δ
Lankisch, T. O., Metzger, J., Negm, A. A., Voβkuhl, K., Schiffer, E., Siwy, J., Weismüller, T. J., Schneider, A. S., Thedieck, K., Baumeister, R., et al. (2010) · Hepatology · doi:10.1002/hep.24103 · Cited by 162
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol
Kiefer, M. V., Albert, M., McNally, M., Robertson, M. C., Sun, W., Fraker, D. L., Olthoff, K. M., Christians, K. K., Pappas, S. G., Rilling, W. S., et al. (2010) · Cancer · doi:10.1002/cncr.25625 · Cited by 161
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Gani, F., Nagarajan, N., Kim, Y., Zhu, Q., Luan, L., Bhaijee, F., Anders, R. A., & Pawlik, T. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5101-y · Cited by 155
Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
Rafi, S., Piduru, S. M., El‐Rayes, B. F., Kauh, J. S. W., Kooby, D. A., Sarmiento, J. M., & Kim, H. S. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-012-0463-4 · Cited by 155
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
Gingras, M., Covington, K. R., Chang, D. K.-F., Donehower, L. A., Gill, A. J., Ittmann, M., Creighton, C. J., Johns, A. L., Shinbrot, E., Dewal, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.005 · Cited by 152
Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma
Park, S.-Y., Kim, J. H., Yoon, H.-J., Lee, I., Yoon, H., & Kim, K.-P. (2011) · Clinical Radiology · doi:10.1016/j.crad.2010.11.002 · Cited by 152
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 150
An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples
Fritcher, E. G. B., Voss, J. S., Brankley, S. M., Campion, M. B., Jenkins, S. M., Keeney, M. E., Henry, M. R., Kerr, S., Chaiteerakij, R., Pestova, E. V., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.046 · Cited by 148
Self-citation
Immunotherapy against cancer-related viruses
Tashiro, H., & Brenner, M. K. (2016) · Cell Research · doi:10.1038/cr.2016.153 · Cited by 147
525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
Bang, Y., Doi, T., de Braud, F., Piha-Paul, S. A., Hollebecque, A., Razak, A. R. A., Lin, C., Ott, P., He, A. R., Yuan, S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30326-4 · Cited by 145
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success
Vogl, T. J., Naguib, N. N. N., Nour-Eldin, N.-E. A., Bechstein, W. O., Zeuzem, S., Trojan, J., & Gruber‐Rouh, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.26407 · Cited by 144
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
Metzger, J., Negm, A. A., Plentz, R. R., Weismüller, T. J., Wedemeyer, J., Karlsen, T. H., Dakna, M., Mullen, W., Mischak, H., Manns, M. P., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302047 · Cited by 137
A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe
Bertuccio, P., Bosetti, C., Levi, F., Decarli, A., Negri, E., & Vecchia, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds652 · Cited by 135
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Goeppert, B. F., Frauenschuh, L., Renner, M., Roessler, S. K., Stenzinger, A., Klauschen, F., Warth, A., Vogel, M. N., Mehrabi, A., Hafezi, M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.206 · Cited by 133
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Golan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 130
Self-citation
Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis
Tanaka, A., Tazuma, S., Okazaki, K., Nakazawa, T., Inui, K., Chiba, T., & Takikawa, H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.12.038 · Cited by 125
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 125
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis
Iavarone, M. A., Piscaglia, F., Vavassori, S., Galassi, M., Sangiovanni, A., Venerandi, L., Forzenigo, L. V., Golfieri, R., Bolondi, L., & Colombo, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.013 · Cited by 124
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
El-Khoueiry, A. B., Rankin, C. J., Siegel, A. B., Iqbal, S., Gong, I.-Y., Micetich, K. C., Kayaleh, O. R., Lenz, H. J., & Blanke, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.801 · Cited by 122
Treatment of unresectable cholangiocarcinoma
Kuhlmann, J. B., Euringer, W., Spangenberg, H. C., Breidert, M., Blum, H. E., Harder, J., & Fischer, R. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283502241 · Cited by 122
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
Goyal, L., Zheng, H., Yurgelun, M. B. B., Abrams, T. A., Allen, J. N., Cleary, J. M., Knowles, M., Regan, E. M., Reardon, A., Khachatryan, A., et al. (2017) · Cancer · doi:10.1002/cncr.30571 · Cited by 121
Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion – An extension of the ALPPS approach
Tschuor, C., Croome, K. P., Sergeant, G., Cano, V., Schadde, E., Ardiles, V., Slankamenac, K., Clariá, R. S., de Santibáñes, E., Hernandez‐Alejandro, R., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.009 · Cited by 118
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
Andresen, K., Boberg, K. M., Vedeld, H. M., Honne, H., Jebsen, P., Hektoen, M., Wadsworth, C. A., Clausen, O. P. F., Lundin, K. E. A., Paulsen, V., et al. (2015) · Hepatology · doi:10.1002/hep.27707 · Cited by 115
Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.
Edeline, J., Bonnetain, F., Phelip, J., Watelet, J., Hammel, P. R., Joly, J., Abdelghani, M. B., Rosmorduc, O., Bouhier‐Leporrier, K., Jouve, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.225 · Cited by 110
Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy
Dudley, J. C., Zheng, Z., McDonald, T. O., Le, L. P., Dias-Santagata, D. C., Borger, D. R., Batten, J. M., Vernovsky, K., Sweeney, B. J., Arpin, R., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.08.002 · Cited by 109
Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance
Crane, C. H., & Koay, E. J. (2016) · Cancer · doi:10.1002/cncr.29878 · Cited by 108
MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings
Masselli, G., Manfredi, R. M., Vecchioli, A., & Gualdi, G. (2008) · European Radiology · doi:10.1007/s00330-008-1004-z · Cited by 107
Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses
Severino, V., Dumonceau, J., Delhaye, M., Moll, S., Annessi-Ramseyer, I., Robin, X., Frossard, J., & Farina, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.043 · Cited by 101
Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
Feldman, S. A., Assadipour, Y., Kriley, I. R., Goff, S. L., & Rosenberg, S. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.005 · Cited by 100
Staging cholangiocarcinoma by imaging studies
Vilgrain, V. (2008) · HPB · doi:10.1080/13651820801992617 · Cited by 98
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness
Brivio, S., Cadamuro, M., Strazzabosco, M., & Fabris, L. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i9.455 · Cited by 98
A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
Ilyas, S. I., Yamada, D., Hirsova, P., Bronk, S. F., Werneburg, N. W., Krishnan, A., Salim, W., Zhang, L. N., Trushina, E. V., Truty, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698472 · Cited by 94
Self-citation
Incidence Rates of Intra- and Extrahepatic Cholangiocarcinomas in Denmark From 1978 Through 2002
Jepsen, P., Vilstrup, H., Tarone, R. E., Friis, S., & Sørensen, H. T. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk201 · Cited by 91
Descriptive epidemiology of cholangiocarcinoma in Italy
Alvaro, D., Crocetti, E., Ferretti, S., Bragazzi, M. C., & Capocaccia, R. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.10.009 · Cited by 88
Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts
Raggi, C., Invernizzi, P., & Andersen, J. B. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.007 · Cited by 87
Portal Vein Resection in Management of Hilar Cholangiocarcinoma
Hemming, A. W., Mekeel, K. L., Khanna, A., Baquerizo, A., & Kim, R. D. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.12.028 · Cited by 87
Radiotherapy Is Associated With Improved Survival in Adjuvant and Palliative Treatment of Extrahepatic Cholangiocarcinomas
Shinohara, E. T., Mitra, N., Guo, M., & Metz, J. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.09.017 · Cited by 86
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
Pant, S., Saleh, M. N., Bendell, J. C., Infante, J. R., Jones, S. F., Kurkjian, C. D., Moore, K. N., Kazakin, J., Abbadessa, G., Wang, Y., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu157 · Cited by 84
Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States
Altekruse, S. F., Petrick, J. L., Rolin, A. I., Cucinelli, J. E., Zou, Z., Tatalovich, Z., & McGlynn, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120574 · Cited by 79
Typical and Atypical Imaging Findings of Intrahepatic Cholangiocarcinoma Using Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid–Enhanced Magnetic Resonance Imaging
Kim, S., Lee, C. H., Kim, B. H., Kim, W. B., Yeom, S. K., Kim, K. A., & Park, C. M. (2012) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e3182706562 · Cited by 79
Trends in the incidence and management of biliary tract cancer: A French population-based study
Lepage, C., Cottet, V., Chauvenet, M., Phelip, J., Bedenne, L., Faivre, J., & Bouvier, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.039 · Cited by 79
FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism
Acquaviva, J., He, S., Zhang, C., Jimenez, J.-P., Nagai, M., Sang, J., Sequeira, M., Smith, D. L., Ogawa, L. S., Inoue, T., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0004 · Cited by 75
Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target
Saborowski, A. L., Saborowski, M., Davare, M. A., Druker, B. J., Klimstra, D. S., & Lowe, S. W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311707110 · Cited by 73
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
Bridgewater, J. A., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. S., & Valle, J. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2174-8 · Cited by 72
Enhancer of Zeste Homolog 2 (EZH2) Promotes Progression of Cholangiocarcinoma Cells by Regulating Cell Cycle and Apoptosis
Nakagawa, S., Okabe, H., Sakamoto, Y., Hayashi, H., Hashimoto, D., Yokoyama, N., Sakamoto, K., Kuroki, H., Mima, K., Nitta, H., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3135-y · Cited by 67
Radiotherapy in the Treatment of Patients With Unresectable Extrahepatic Cholangiocarcinoma
Ghafoori, A. P., Nelson, J. W., Willett, C. G., Chino, J., Tyler, D. S., Hurwitz, H. I., Uronis, H. E., Morse, M. A., Clough, R. W., & Czito, B. G. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.018 · Cited by 67
Intrahepatic cholangiocarcinoma: indication for transplantation
Pascher, A., Jonas, S., & Neuhaus, P. (2003) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-002-0731-9 · Cited by 66
Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment
Li, Y., Li, H., Lv, P., Liu, G., Li, X., Tian, B., & Chen, D. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1419-8 · Cited by 66
Cholangiocarcinoma: increasing burden of classifications.
Cardinale, V., Bragazzi, M. C., Carpino, G., Torrice, A., Fraveto, A., Gentile, R., Pasqualino, V., Melandro, F., Aliberti, C., Bastianelli, C., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2013.10.02 · Cited by 62
Hepatic Resection in the Treatment of Hilar Cholangiocarcinoma
Nagorney, D. M., & Kendrick, M. L. (2006) · Advances in Surgery · doi:10.1016/j.yasu.2006.05.009 · Cited by 61
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Kawamata, F., Kamachi, H., Einama, T., Homma, S., Tahara, M., MIYAZAKI, M., Tanaka, S., Kamiyama, T., Nishihara, H., Taketomi, A., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1662 · Cited by 61
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells
Baradari, V. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i33.4458 · Cited by 57
Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis
Ilyas, S. I., Mertens, J. C., Bronk, S. F., Hirsova, P., Dai, H., Roberts, L. R., Kaufmann, S. H., & Gores, G. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563064 · Cited by 56
Self-citation
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
Javle, M. M., Shroff, R. T., Zhu, A. X., Sadeghi, S., Choo, S., Borad, M. J., Lowery, M. A., El-Khoueiry, A. B., Macarulla, T. M., Philip, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.335 · Cited by 55
Mutation Profile and Fluorescence In Situ Hybridization Analyses Increase Detection of Malignancies in Biliary Strictures
Gonda, T. A., Viterbo, D., Gausman, V., Kipp, C., Sethi, A., Poneros, J. M., Gress, F. G., Park, T., Khan, A., Jackson, S. A., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.12.013 · Cited by 49
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Nakagawa, S., Sakamoto, Y., OKABE, H., Hayashi, H., Hashimoto, D., Yokoyama, N., Tokunaga, R., Sakamoto, K., Kuroki, H., Mima, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2922 · Cited by 48
The underreporting of hepatocellular carcinoma to the cancer register and a log‐linear model to estimate a more correct incidence
Törner, A., Stokkeland, K., Svensson, Å., Dickman, P. W., Hultcrantz, R. W., Montgomery, S., & Duberg, A. (2016) · Hepatology · doi:10.1002/hep.28775 · Cited by 48
Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge
Naboush, A., Roman, C. A. J., & Shapira, I. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000342 · Cited by 48
Epigenome dysregulation in cholangiocarcinoma
O’Rourke, C. J., Muñoz-Garrido, P., Aguayo, E. L., & Andersen, J. B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.014 · Cited by 48
Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
Kwak, T. W., Kim, D. H., Jeong, Y., & Kang, D. H. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0122-4 · Cited by 46
Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma
Mukewar, S. S., Gupta, A., Baron, T. H., Gores, G. J., Furutani, K. M., Haddock, M. G., & Hallemeier, C. L. (2015) · Endoscopy · doi:10.1055/s-0034-1392044 · Cited by 46
Self-citation
Mesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma
Nomura, R., Fujii, H., Abe, M., Sugo, H., Ishizaki, Y., Kawasaki, S., & Hino, O. (2013) · International Surgery · doi:10.9738/intsurg-d-13-00001.1 · Cited by 44
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Iwahashi, S., Utsunomiya, T., Imura, S., Morine, Y., Ikemoto, T., Arakawa, Y., Saito, Y., Ishikawa, D., & Shimada, M. (2014) · PubMed · Cited by 41
Does radiotherapy still have a role in unresected biliary tract cancer?
Pollom, E. L., Alagappan, M., Park, L. S., Whittemore, A. S., Koong, A. C., & Chang, D. T. (2016) · Cancer Medicine · doi:10.1002/cam4.975 · Cited by 39
Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers
Kilander, C., Mattsson, F., Ljung, R., Lagergren, J., & Sadr‐Azodi, O. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.857429 · Cited by 37
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Burris, H. A., Mellinghoff, I. K., Maher, E. A., Wen, P. Y., Beeram, M., Touat, M., Faris, J. E., Azad, N. S., Cloughesy, T. F., Gore, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-pl04-05 · Cited by 36
Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas
Sasaki, M., Nitta, T., Sato, Y., & Nakanuma, Y. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw071 · Cited by 34
PBRM1 loss is a late event during the development of cholangiocarcinoma
Luchini, C., Robertson, S., Hong, S., Felsenstein, M., Anders, R. A., Pea, A., Nottegar, A., Veronese, N., He, J. P., Weiss, M. J., et al. (2017) · Histopathology · doi:10.1111/his.13234 · Cited by 32
Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival
Hammad, A. Y., Berger, N. G., Eastwood, D. C., Tsai, S., Turaga, K. K., Christian, K. K., Johnston, F. M., Pawlik, T. M., & Gamblin, T. C. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5560-1 · Cited by 32
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 31
Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings
Sriraksa, R., & Limpaiboon, T. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2503 · Cited by 26
EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3
Tang, B., Du, J., Li, Y., Tang, F., Wang, Z., & He, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0271-6 · Cited by 25
The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: A retrospective cohort study
Hong, Y., Choi, S., Lee, K. H., Park, S. W., Park, Y. N., Choi, J. S., Lee, W. J., Chung, J. B., & Kim, K. S. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.12.010 · Cited by 24
Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma.
Jia, A. Y., Wu, J., Zhao, Y.-T., Li, Y., Wang, Z., Rong, W., Wang, L., Jin, J., Wang, S., Song, Y.-W., et al. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.102 · Cited by 19
Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers
Santana-Dávila, R., Bhatia, S., & Chow, L. Q. M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4574 · Cited by 17
Sodium Valproate Inhibits the Growth of Human CholangiocarcinomaIn VitroandIn Vivo
Wang, B., Yang, R., Wu, Y., Li, H., Hu, Z., Chen, Y., & Shengquan, Z. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/374593 · Cited by 17
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
Thomas, D., & Majeti, R. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0270 · Cited by 16
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
Ott, P. A., & Hodi, F. S. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.05 · Cited by 10
Detection of Cholangiocarcinoma by Assay of Methylated DNA Markers in Plasma
Yang, J. D., Yab, T. C., Taylor, W. R., Foote, P. H., Ali, H. A., Lavu, S., Simonson, J. A., Burger, K. N., Mahoney, D. W., Slettedahl, S. W., et al. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)33526-6 · Cited by 8
Self-citation
Another solution that enables ablative radiotherapy for large liver tumors: Percutaneous interstitial high‐dose rate brachytherapy
Patel, S., Ragab, O. M., & Kamrava, M. R. (2016) · Cancer · doi:10.1002/cncr.30128 · Cited by 4
Misleading figures on trends in mortality from hepatocellular carcinoma in europe†
Duberg, A., & Hultcrantz, R. W. (2008) · Hepatology · doi:10.1002/hep.22671 · Cited by 2

Sorted by citations

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Self-citation
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,159
Self-citation
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Cholangiocarcinoma
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A. C., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 895
Self-citation
Cholangiocarcinoma: Epidemiology and risk factors
Khan, S. A., Tavolari, S., & Brandi, G. (2019) · Liver International · doi:10.1111/liv.14095 · Cited by 804
Self-citation

See all 1,626

Authors: Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J.
Affiliations: Mayo Clinic (US)
Hammersmith Hospital (GB)
University of California San Francisco Medical Center (US)
Corresponding author: Gores, Gregory J.
ORCID: Ilyas, Sumera I.
Khan, Shahid A.
Hallemeier, Christopher L.
Kelley, Robin K.
Gores, Gregory J.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-10
Volume: 15
Issue: 2
Pages: 95-111
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.157
PMC: PMC5819599
OpenAlex: W2763492611
Cited by: 1,626
References: 175
Citations by year: 2026: 88 · 2025: 164 · 2024: 252 · 2023: 247 · 2022: 253 · 2021: 272 · 2020: 209 · 2019: 82 · 2018: 51 · 2017: 1
FWCI: 19.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Cholangiocarcinoma Foundation
National Institutes of Health
Institute of Chemistry, Chinese Academy of Sciences
National Cancer Institute (R03CA212877)
National Institute of Diabetes and Digestive and Kidney Diseases (R56DK059427, R01DK059427, P30DK084567)
Topics: Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: cholangiocarcinoma, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma, pathogenesis, surgical resection, liver transplantation, neoadjuvant chemoradiotherapy, locoregional chemotherapy, external beam radiotherapy, genetic landscape, molecular targets, precision medicine, immunotherapy, tumor stroma, biomarkers
MeSH terms: Adult, Cell Differentiation, Humans, Liver Neoplasms, Prognosis, Liver Transplantation, Cholangiocarcinoma, Neoadjuvant Therapy, Precision Medicine, Molecular Targeted Therapy, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks